Plasma C-peptide response to oral glucose in low insulin responders, subdiabetic, and diabetic subjects. 1977

T Toyota, and M Kudo, and K Abe, and Y Goto

It is one of the characteristic features in diabetes mellitus that insulin response to glucose is low. Nine low insulin responders with normal glucose tolerance in whom prediabetes mellitus should be suspected were found to be included in 104 apparently healthy subjects (9%). A 100 g glucose tolerance test (GTT) was performed in nine apparently healthy subjects with a low insulin response and 11 healthy subjects with a normal insulin response. A 50 g GTT was performed in 15 normal subjects, 20 subdiabetics, 38 chemical diabetics and 17 mild diabetics. In all subjects C-peptide during GTT was estimated by the double antibody systems using a synthetic human C-peptide. Though C-peptide secretion from the beta cell of the pancreas seems to keep pace with insulin secretion, the peak of C-peptide was delayed in its appearance in the circulating blood, as compared with that of insulin. The pattern of plasma C-peptide during GTT in diabetics was identical with that of insulin. In the low insulin responders C-peptide response to glucose was observed to be lower like that of insulin than in the normal insulin responders. However, a molar ratio of C-peptide to insulin at 30 min during GTT in the former was higher than that in the latter.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D010179 Pancreas A nodular organ in the ABDOMEN that contains a mixture of ENDOCRINE GLANDS and EXOCRINE GLANDS. The small endocrine portion consists of the ISLETS OF LANGERHANS secreting a number of hormones into the blood stream. The large exocrine portion (EXOCRINE PANCREAS) is a compound acinar gland that secretes several digestive enzymes into the pancreatic ductal system that empties into the DUODENUM.
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D011236 Prediabetic State The time period before the development of symptomatic diabetes. For example, certain risk factors can be observed in subjects who subsequently develop INSULIN RESISTANCE as in type 2 diabetes (DIABETES MELLITUS, TYPE 2). Prediabetes,Prediabetic States,State, Prediabetic,States, Prediabetic
D002096 C-Peptide The middle segment of proinsulin that is between the N-terminal B-chain and the C-terminal A-chain. It is a pancreatic peptide of about 31 residues, depending on the species. Upon proteolytic cleavage of proinsulin, equimolar INSULIN and C-peptide are released. C-peptide immunoassay has been used to assess pancreatic beta cell function in diabetic patients with circulating insulin antibodies or exogenous insulin. Half-life of C-peptide is 30 min, almost 8 times that of insulin. Proinsulin C-Peptide,C-Peptide, Proinsulin,Connecting Peptide,C Peptide,C Peptide, Proinsulin,Proinsulin C Peptide
D003920 Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005947 Glucose A primary source of energy for living organisms. It is naturally occurring and is found in fruits and other parts of plants in its free state. It is used therapeutically in fluid and nutrient replacement. Dextrose,Anhydrous Dextrose,D-Glucose,Glucose Monohydrate,Glucose, (DL)-Isomer,Glucose, (alpha-D)-Isomer,Glucose, (beta-D)-Isomer,D Glucose,Dextrose, Anhydrous,Monohydrate, Glucose
D005951 Glucose Tolerance Test A test to determine the ability of an individual to maintain HOMEOSTASIS of BLOOD GLUCOSE. It includes measuring blood glucose levels in a fasting state, and at prescribed intervals before and after oral glucose intake (75 or 100 g) or intravenous infusion (0.5 g/kg). Intravenous Glucose Tolerance,Intravenous Glucose Tolerance Test,OGTT,Oral Glucose Tolerance,Oral Glucose Tolerance Test,Glucose Tolerance Tests,Glucose Tolerance, Oral
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

T Toyota, and M Kudo, and K Abe, and Y Goto
January 1980, Journal of endocrinological investigation,
T Toyota, and M Kudo, and K Abe, and Y Goto
May 1983, Diabetes,
T Toyota, and M Kudo, and K Abe, and Y Goto
January 1989, Experimental and clinical endocrinology,
T Toyota, and M Kudo, and K Abe, and Y Goto
December 1980, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
T Toyota, and M Kudo, and K Abe, and Y Goto
January 1990, Journal of endocrinological investigation,
T Toyota, and M Kudo, and K Abe, and Y Goto
September 1983, Acta endocrinologica,
Copied contents to your clipboard!